Latest article on GI Pathology for JC presentation
Asking for Preferences
Searching PubMed
"gastric cancer"[MeSH Terms] AND cohort
Searching PubMed
"stomach neoplasms"[MeSH Terms] AND observational study
Reading Article
PMID: 40555751
Reading Article
PMID: 40632416
Reading Article
PMID: 40889068
Here are the top recent gastric cancer observational studies for your Journal Club presentation:
Top Gastric Cancer Observational Studies (2025-2026) for JC
🥇 Recommended Pick 1 - High Impact, Novel Topic
"AI-based large-scale screening of gastric cancer from noncontrast CT imaging"
Hu C, Xia Y, et al. | Nature Medicine | 2025
PMID: 40555751 | DOI: 10.1038/s41591-025-03785-6
Why it's great for JC:
- Published in Nature Medicine - highest-impact journal in this list
- Multicenter observational study across 18 centers, 78,593 CT scans in real-world screening
- Developed GRAPE (Gastric Cancer Risk Assessment Procedure with AI using deep learning on noncontrast CT)
- AUC 0.970 (internal) and 0.927 (external validation)
- GRAPE outperformed radiologists: +21.8% sensitivity, +14.0% specificity - especially for early-stage GC
- Detected cases radiologists initially missed; 23-27% of detected cases were T1/T2 stage
- Discussion-rich topic: AI in GI pathology screening, opportunistic screening, resource-limited settings
🥈 Recommended Pick 2 - Clinical/Therapeutic Real-World Data
"Nivolumab + chemotherapy for untreated advanced/recurrent gastric cancer in real-world settings: the G-KNIGHT study"
Kadowaki S, Otsuka T, et al. | Gastric Cancer | 2025
PMID: 40632416 | DOI: 10.1007/s10120-025-01641-7
⚠️ Note: An erratum has been published (PMID: 42313301) - worth checking before presentation.
Why it's good for JC:
- Large-scale multicenter observational study, n = 527 patients, 23 Japanese centers
- Real-world effectiveness of nivolumab (immunotherapy) + chemotherapy as first-line treatment
- ORR 65.6%, median rwPFS 6.9 months
- Subgroup analysis by age (including elderly ≥75 yrs) and PD-L1 CPS score
- Grade ≥3 TRAEs in 40.4% - safety profile in real-world vs clinical trial populations
- Discussion point: Trial-to-practice gap, PD-L1 as a biomarker in GC
🥉 Recommended Pick 3 - Translational/Biomarker Focus
"Circulating Tumor DNA Profiling Reveals Genomic Evolution in Recurrent Gastric or Gastroesophageal Junction Cancer"
Kawabata R, Takeda H, et al. | Molecular Diagnosis & Therapy | 2025
PMID: 40889068 | DOI: 10.1007/s40291-025-00807-4
Why it's good for JC:
- Prospective multicenter observational study, n = 50 patients
- ctDNA (liquid biopsy via Guardant360) vs archival tumor tissue at recurrence
- Actionable genomic alterations found in 36% by ctDNA
- 66.7% of patients showed changes in actionable alterations between primary tumor and recurrence
- New ERBB2 amplifications and PIK3CA mutations found only in ctDNA at recurrence
- Discussion point: Clonal evolution, liquid biopsy utility, precision oncology in GC
Quick Comparison Table
| GRAPE (Nature Med) | G-KNIGHT | ctDNA Study | |
|---|---|---|---|
| Design | Multicenter observational | Multicenter observational | Prospective multicenter observational |
| n | 78,593 CT scans | 527 patients | 50 patients |
| Focus | Screening / AI | Immunotherapy (real-world) | Biomarker / liquid biopsy |
| Pathology angle | Radiological-pathological correlation | Clinical outcomes | Genomic pathology |
| JC richness | ★★★★★ | ★★★★ | ★★★★ |
| Erratum? | No | Yes (check PMID 42313301) | No |
My top recommendation for a GI Pathology JC: the GRAPE study (PMID 40555751) - it's in Nature Medicine, has a large sample, introduces a genuinely novel pathology-adjacent screening technology, and generates great discussion on AI, early detection, and T-staging pathology. The ctDNA study (PMID 40889068) is the best pick if your JC has a molecular/translational pathology flavor.
This is a shared conversation. Sign in to Orris to start your own chat.